Empagliflozin for Kidney Failure
(SEED Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing empagliflozin, a medication that lowers blood sugar, in patients with severe kidney disease who are beginning treatment. The goal is to see if it is safe and effective for these patients. Empagliflozin helps the body get rid of extra sugar through urine.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot use an SGLT2 inhibitor within 6 weeks before joining the study. Also, you cannot use both an ACE inhibitor and an angiotensin receptor blocker together.
Is empagliflozin safe for humans?
How does the drug empagliflozin differ from other treatments for kidney failure?
What evidence supports the effectiveness of the drug empagliflozin for kidney failure?
Who Is on the Research Team?
David Charytan, MS, MSc
Principal Investigator
NYU Langone Health
Are You a Good Fit for This Trial?
Adults over 18 who recently started hemodialysis for end-stage kidney disease can join this trial. They must be able to consent and, if female and able to have children, show a negative pregnancy test. People with plans for a kidney transplant soon, severe heart failure, recent major cardiovascular events or surgery, certain diabetes types or complications, active serious infections or cancer treatments are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Empagliflozin or placebo daily for 12 weeks while initiating hemodialysis
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Empagliflozin 10 MG
- Placebo
Empagliflozin 10 MG is already approved in United States, European Union for the following indications:
- Type 2 diabetes
- Heart failure
- Chronic kidney disease
- Type 2 diabetes
- Heart failure
- Chronic kidney disease
Find a Clinic Near You
Who Is Running the Clinical Trial?
NYU Langone Health
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator
Boehringer Ingelheim
Industry Sponsor